Anika Therapeutics ANIK Europe — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's europe — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's europe — revenue?
- Anika Therapeutics (ANIK) reported europe — revenue of $6.67M in Q1 2026.
- How has Anika Therapeutics's europe — revenue changed year-over-year?
- Anika Therapeutics's europe — revenue increased by 15.0% year-over-year, from $5.8M to $6.67M.
- What is the long-term trend for Anika Therapeutics's europe — revenue?
- Over 4 years (2021 to 2025), Anika Therapeutics's europe — revenue has grown at a 3.2% compound annual growth rate (CAGR), from $19.58M to $22.21M.
- What does europe — revenue mean?
- This metric represents the total revenue generated from contracts with customers within the European geographic segment, excluding any assessed taxes such as sales or value-added taxes. It serves as a primary indicator of the company's commercial performance and market penetration in the European orthopedic medicine market. Tracking this figure allows investors to assess the underlying growth trajectory of the business independent of regional tax fluctuations.